Back

Parabrachial CGRP Neurons Regulate Opioid Reinforcement

Bystrom, L. L.; Margetts, A. V.; Kujas, N. M.; Bourgain-Guglielmetti, F. M.; Marinov, E. P.; Tuesta, L. M.

2026-03-20 neuroscience
10.64898/2026.03.18.712659 bioRxiv
Show abstract

Opioid use disorder (OUD) is a chronic, relapsing disease driven by the reinforcing properties of opioids and perpetuated by avoidance of the negative affective states associated with the absence of the drug. Most available OUD treatments directly engage the {micro}-opioid receptor and may induce side effects that can compromise their therapeutic efficacy, thus underscoring the need for novel therapeutic alternatives. Calcitonin gene-related peptide (CGRP) is produced by a small population of neurons in the parabrachial nucleus (PBN) that has been shown to modulate itch, pain, as well as appetitive behaviors. Using a cell-specific nuclear labeling approach coupled with RNA-sequencing, we generated a baseline transcriptome of CGRPPBN neurons and confirmed expression of multiple genes associated with behavioral responses to appetitive stimuli, as well as enrichment of the {micro}-opioid receptor, suggesting that CGRPPBN neuron function may be sensitive to the presence of opioids. Indeed, cFos immunostaining showed that CGRPPBN neuron activity increases during early morphine abstinence and reduces gradually over 48 hours. Given the inhibitory effects of opioids on CGRPPBN neuron activity, we next tested whether these neurons could regulate opioid reinforcement. Using a mouse model of morphine intravenous self-administration, we found that chemogenetic inhibition of CGRPPBN neurons significantly reduced the number of morphine rewards earned in both single-dose and dose-response tests but did not affect context-induced morphine seeking after 21 days of abstinence. These results suggest that CGRPPBN neurons are sensitive to opioid administration and can regulate appetitive behaviors such as morphine-taking. Considering that CGRP signaling is regulated by opioid administration, molecular targets that regulate CGRP neurotransmission without direct -opioid receptor engagement may therefore serve as novel therapeutic avenues for the treatment of OUD. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/712659v1_ufig1.gif" ALT="Figure 1"> View larger version (56K): org.highwire.dtl.DTLVardef@1fb9c9borg.highwire.dtl.DTLVardef@1e6ba79org.highwire.dtl.DTLVardef@dc60f5org.highwire.dtl.DTLVardef@61adaf_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Addiction Biology
47 papers in training set
Top 0.1%
22.2%
2
Neuropharmacology
60 papers in training set
Top 0.1%
10.0%
3
Neuropsychopharmacology
134 papers in training set
Top 0.4%
6.7%
4
Addiction Neuroscience
17 papers in training set
Top 0.1%
6.3%
5
Psychopharmacology
59 papers in training set
Top 0.1%
6.2%
50% of probability mass above
6
eLife
5422 papers in training set
Top 23%
3.9%
7
International Journal of Molecular Sciences
453 papers in training set
Top 3%
3.5%
8
British Journal of Pharmacology
34 papers in training set
Top 0.1%
2.7%
9
Translational Psychiatry
219 papers in training set
Top 2%
2.7%
10
Biological Psychiatry
119 papers in training set
Top 1%
2.6%
11
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
1.8%
12
Pharmacology Biochemistry and Behavior
17 papers in training set
Top 0.2%
1.7%
13
Molecular Psychiatry
242 papers in training set
Top 2%
1.7%
14
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.5%
15
Behavioural Brain Research
70 papers in training set
Top 0.7%
1.3%
16
Scientific Reports
3102 papers in training set
Top 65%
1.3%
17
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.8%
0.9%
18
Neuroscience
88 papers in training set
Top 2%
0.9%
19
Pain
70 papers in training set
Top 0.7%
0.9%
20
Journal of Psychopharmacology
14 papers in training set
Top 0.5%
0.9%
21
Neurotherapeutics
11 papers in training set
Top 0.5%
0.8%
22
Frontiers in Behavioral Neuroscience
46 papers in training set
Top 0.9%
0.8%
23
ACS Chemical Neuroscience
60 papers in training set
Top 2%
0.8%
24
eneuro
389 papers in training set
Top 9%
0.7%
25
European Neuropsychopharmacology
15 papers in training set
Top 0.6%
0.7%
26
Biological Psychiatry Global Open Science
54 papers in training set
Top 2%
0.7%
27
Science Advances
1098 papers in training set
Top 32%
0.7%